Dithranol: An Insight into its Novel Delivery Cargos for Psoriasis Management

Author(s): Varsha Kadian, Sunil Kumar, Komal Saini, Vandita Kakkar, Rekha Rao*

Journal Name: Current Drug Research Reviews
(Formerly Current Drug Abuse Reviews)

Volume 12 , Issue 2 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Objective: Dithranol (DTH) is a well-known moiety that has long been used promisingly to impede and treat skin disorders, particularly psoriasis. Nowadays, a rekindled interest in the use of DTH for this disorder has been observed. Side effects associated with conventional topical formulations of this moiety have aroused the interest of the scientific community in investigating novel cargos of DTH for psoriasis management.

Results: Previous research has evidenced the anti-inflammatory and anti-proliferating potential of DTH. Numerous studies have indicated that DTH inhibits polymorphonuclear (PMN) leucocyte, modulates epidermal cell receptors and promotes anti-psoriatic action. However, some deterrent factors like poor solubility, stability, toxicity, staining and skin irritation hamper its use as a potential therapeutic agent. With the adoption of novel drug delivery technologies, the above mentioned inherent limitations of DTH have been compensated to reestablish this drug moiety.

Conclusion: This article reviews novel drug delivery aspects, safety concerns, clinical evidence, current status, and future opportunities of DTH in the management of psoriasis. Further, it will update researchers on this promising drug moiety, which is free from systemic adverse responses in comparison to other therapeutic molecules like steroids, for psoriasis treatment.

Keywords: Dithranol, anti-psoriatic potential, delivery systems, safety concerns, pharmacokinetics, clinical aspects.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 11 January, 2021
Page: [82 - 96]
Pages: 15
DOI: 10.2174/2589977512666200525154954
Price: $65

Article Metrics

PDF: 13